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ABSTRACT
Background Acute tubulointerstitial nephritis (TIN) is 
a significant cause of acute renal failure in paediatric 
and adult patients. There are no large paediatric series 
focusing on the aetiology, treatment and courses of acute 
TIN.
Patients, design and setting We collected retrospective 
clinical data from paediatric patients with acute biopsy- 
proven TIN by means of an online survey. Members of four 
professional societies were invited to participate.
Results Thirty- nine physicians from 18 countries 
responded. 171 patients with acute TIN were included 
(54% female, median age 12 years). The most frequent 
causes were tubulointerstitial nephritis and uveitis syndrome 
in 31% and drug- induced TIN in 30% (the majority of these 
caused by non- steroidal anti- inflammatory drugs). In 28% 
of patients, no initiating noxae were identified (idiopathic 
TIN). Median estimated glomerular filtration rate (eGFR) 
rose significantly from 31 at time of renal biopsy to 86 mL/
min/1.73 m2 3–6 months later (p<0.001). After 3–6 months, 
eGFR normalised in 41% of patients (eGFR ≥90 mL/
min/1.73 m2), with only 3% having severe or end- stage 
impairment of renal function (<30 mL/min/1.73 m2). 80% 
of patients received corticosteroid therapy. Median eGFR 
after 3–6 months did not differ between steroid- treated 
and steroid- untreated patients. Other immunosuppressants 
were used in 18% (n=31) of patients, 21 of whom received 
mycophenolate mofetil.
Conclusions Despite different aetiologies, acute 
paediatric TIN had a favourable outcome overall with 88% 
of patients showing no or mild impairment of eGFR after 
3–6 months. Prospective randomised controlled trials are 
needed to evaluate the efficacy of glucocorticoid treatment 
in paediatric patients with acute TIN.
INTRODUCTION
Acute tubulointerstitial nephritis (TIN) is 
a significant cause of acute renal failure in 
paediatric and adult patients. TIN accounts 
for approximately 2%–3% of native renal 
biopsies.1–3 In biopsies to evaluate acute renal 
failure of unknown origin, TIN represents 
about 13% of cases in adult patients.2 3 Reli-
able data on the incidence and prevalence of 
paediatric TIN are lacking.
Renal histopathology in TIN is charac-
terised by interstitial cellular infiltrates and 
oedema, but vessels and glomeruli are typi-
cally spared.4 The inflammatory process may 
eventually lead to interstitial fibrosis and 
chronic kidney disease.5
Numerous causes of TIN are known, 
with drugs, especially non- steroidal anti- 
inflammatory drugs (NSAIDs), being the 
trigger in 60%–70% of cases6; however, the 
identity of the causative agent in cases of TIN 
is usually speculative. Other cases of TIN are 
related to infections or systemic diseases. In 
some cases, renal disease can be accompa-
nied by uveal inflammation (tubulointerstitial 
nephritis with uveitis (TINU)).7 8 Other TIN 
cases are presumed to be idiopathic.4 Despite 
Strengths and limitations of this study
 ► Largest study on children with tubulointerstitial 
nephritis.
 ► Patients from all parts of the word included as a joint 
project of the most important societies for paediatric 
nephrology.
 ► Retrospective data collected in a survey.
 ► Short follow- up period.
 ► Detailed results of renal biopsy were not available.
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the different aetiologies of TIN, a common immune- 
mediated pathogenic mechanism is assumed. Antigen- 
mediated cellular immune responses seem to play a key 
role in the pathogenesis of TIN.3 9 It is also important to 
note that this is a very heterogeneous group of patients. 
While histopathology is similar, TIN due to sarcoidosis 
is probably biologically distinct entity from that due to 
antibiotics, recreational drugs, NSAIDS and infectious 
agents. Clinical symptoms of TIN are often non- specific 
and therefore may lead to delayed diagnosis and treat-
ment.4 10
Corticosteroids are well established in the treatment of 
severe TIN, although prospective randomised controlled 
clinical trials assessing the indications and efficacy of corti-
costeroid treatment are not available. In adult patients, 
retrospective data indicated beneficial effects of corti-
costeroids on renal function recovery in drug- induced 
TIN.11–14 However, results of other retrospective studies 
did not support the routine administration of corticoste-
roid therapy.1 15 Results from a small prospective paedi-
atric study showed an accelerated renal recovery with 
corticosteroid treatment.16 There is very limited experi-
ence of the use of other immunosuppressive agents (eg, 
mycophenolate mofetil (MMF)) in patients with TIN. 
Moreover, there is no consensus on a standard thera-
peutic regimen (eg, intravenous vs oral administration, 
dosage and duration of therapy) in either children or 
adults.
In this study, we assessed the aetiology, therapy and 
clinical course of TIN in a large paediatric cohort with 
manifestation of acute TIN between 2007 and 2018. Data 
were collected retrospectively via a survey circulated to 
members of the German Society of Pediatric Nephrology 
(GPN), European Society of Pediatric Nephrology 
(ESPN), European Network of Rare Kidney Diseases 
(ERKnet) and Pediatric Nephrology Research Consor-
tium (PNRC) based in the USA.
PATIENTS AND METHODS
Members of GPN, ESPN, ERKNet and PNRC were invited 
to participate in the online survey. An email invitation 
with a summary of the project and a link to an online 
questionnaire service provider (https://www. google. 
de/ intl/ de/ forms/ about/) was sent to all mailing list 
contacts of GPN, ESPN, ERKNet and PNRC. The survey 
was launched in April 2018 and was closed in June 2019.
The data collection was retrospective and fully anony-
mised. Only patients with biopsy- proven TIN were 
included in the study. Further inclusion criteria were age 
between 0 and 18 years, and presentation of disease was 
between 2007 and 2018.
The questionnaire comprised 57 items. Answers were 
given as multiple choice or short free texts assessing the 
incidence, aetiology and course of acute TIN in children. 
‘Yes’, ‘no’ and ‘not assessed’ were given as answer options 
for disease symptoms, urinary findings and biopsy results. 
Free- text answers were required for precise causative 
factors for TIN (eg, drug name, pathogen, underlying 
systemic disease). The questionnaire is provided in the 
online supplemental material.
Creatinine- based ‘Bedside Schwartz’ formula (esti-
mated glomerular filtration rate (eGFR)=0.413 × (height/
Scr)) was used for eGFR.17
The responses were automatically collected in a data-
base provided by the survey administration app. All statis-
tical data analyses were performed in GraphPad Prism V.8 
(https://www. graphpad. com). Continuous variables were 
expressed as median, and range as no normal distribution 
was assumed. Three different non- parametric tests were 
used for analysis of non- normally distributed variables: 
Mann- Whitney U test and Kruskal- Wallis test were used, 
respectively, to compare medians of two groups and three 
or more groups of variables not normally distributed; 
one sample Wilcoxon test was conducted for comparison 
of paired data. Statistical significance of dichotomous 
variables was measured by using the χ2 test. P<0.05 was 
considered statistically significant.
ETHICS APPROVAL
The study was approved by the council of the ESPN, 
GPN, ERKNet and PNRC. Requests for authorisation 
by the ethics committees of the other centres were not 
considered necessary because this was a survey that simply 
collected the experience and practices of the physicians, 
and it did not involve approaching patients directly or 
seeking any patient- specific data.
Patient and public involvement
Patients and public were not involved in the design and 
conduct of this study.
RESULTS
Thirty- nine clinicians from 18 countries participated in 
the survey. One hundred and seventy- one patient cases 
were included in the final analysis. Patients originated 
from Northern Europe (n=41), Southern Europe (n=38), 
Western Europe (n=25), Eastern Europe (n=8), Western 
Asia (n=31), Southern Asia (n=1), Southeastern Asia 
(n=5) and Northern America (n=22).
Gender distribution was equal with 93 (54%) females 
and 78 males (46%). The median age (range) was 13 
(1–17) years at diagnosis with the following age distribu-
tion: 1–5 years: 9% (16/171); 6–12 years: 38% (64/171); 
13–18 years: 53% (91/171) (see figure 1).
Atiology
About one- third of TIN cases was drug related or induced 
by a toxic agent (30%, 52/171). TINU syndrome accounts 
for another third of included cases (31%, 53/171). 
Twenty- eight per cent (48/171) of cases were presumed 
to be idiopathic. Systemic diseases (7%, 11/171) and 
infections (4%, 7/171) were rare causes of acute intersti-
tial nephritis (see figure 2). Infectious causes were most 
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prevalent in patients aged 6–12 years. TIN from other 
causes was predominant in teenage patients (13–18 years) 
(see figure 1).
Drug-induced TIN
NSAIDs and antimicrobials were identified as the most 
common causative drugs and represented 79% (41/52) 
of drug- induced TIN cases. NSAIDs alone accounted for 
48% (25/52) of drug- induced cases, while 10% (5/52) 
of patients received a combination of NSAIDs and anti-
biotics. Twenty- one per cent (11/52) of drug- induced 
cases were based on the administration of antimicrobial 
therapy (antiviral or antibacterial) without comedication. 
Other less frequent substances were identified in 21% 
(11/52) (see table 1).
Median age (13 years, range 1–17) and gender distri-
bution (24/52=46% male, 28/52=54% female) did not 
differ from the total group.
TINU syndrome
TINU syndrome showed a slight predominance in 
females (58%=31/53 female, 42%=22/53 male) without 
statistical significance. Median age of onset was equal to 
the total group (13 years) with an age range between 5 
and 17 years.
Idiopathic TIN
In 28% (48/171) of cases no acute TIN trigger could be 
identified. Median age (range) was 13 years (3–16) with a 
balanced gender distribution of 50% (24/48) males and 
50% (24/48) females.
TIN associated with systemic diseases
Median age (range) of onset was 14 years (1–17). Sixty- 
four per cent (7/11) were female and 36% (4/11) male 
patients. For a complete list of diagnoses see box 1.
TIN associated with infections
Median age (range) was 11 years (1–15), and included 
four male (57%, 4/7) and three female patients (43%, 
3/7). Adenovirus, BK polyoma virus, hepatitis C virus 
and rhinovirus were reported in one patient each. Three 
patients showed symptoms of upper respiratory tract 
infection without pathogen identification.
Clinical and urinary features
Clinical and urinary features in the patient cohort 
are summarised in table 2. The most frequent clinical 
symptom at presentation of disease was fatigue in 70% 
(119/171) of patients, followed by vomiting or nausea 
in 49% (83/169; no data=2) and fever in 43% (73/171) 
Figure 1 Age distribution of 171 patients with acute 
tubulointerstitial nephritis. TINU, tubulointerstitial nephritis 
with uveitis.
Figure 2 Aetiology of acute tubulointerstitial nephritis in 
171 paediatric patients. TINU, tubulointerstitial nephritis with 
uveitis.
Table 1 Drugs and toxic agents as causes of 
tubulointerstitial nephritis (TIN) in 52 patients with acute TIN























NSAIDs, non- steroidal anti- inflammatory drugs.
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of patients. Fourteen per cent (24/169; no data=2) of 
patients showed ocular symptoms at manifestation of 
disease, consistent with the diagnosis of TINU syndrome. 
In 22 of 24 patients with ocular symptoms TINU was diag-
nosed, and vice versa, 58% (31/53) of TINU patients had 
no ocular symptoms at onset of renal disease.
Polyuria, nocturia or enuresis (12 patients), weight 
loss (10 patients) and headache (seven patients) were 
the most frequent additional symptoms given in free- text 
answers.
Histological findings
The most frequent histological findings were interstitial 
infiltration in 95% (162/170; no data=1) and intersti-
tial oedema in 63% (106/167; no data=4) of patients. 
Interstitial granulomas were reported in 6% (11/171) of 
patients, among them drug- induced (four patients), idio-
pathic (four patients) and TINU cases (two patients) and 
one patient with sarcoidosis.
Interstitial fibrosis and tubular atrophy as markers of 
chronic renal damage were seen in 38% (64/170; no 
data=1) and 38% (65/171), respectively, whereas glomer-
ulosclerosis was present in only 7% (12/171) of patients. 
Anonymised copies of original biopsy results were avail-
able in seven cases.
Treatment
Corticosteroids
Eighty per cent of patients (137/171) were treated with 
corticosteroids (intravenous and/or oral); 20% (34/171) 
did not receive any corticosteroids. Forty per cent of 
patients received a combination of intravenous steroids 
followed by oral steroids. Details of corticosteroid treat-
ment in the patient group are summarised in table 3.
Ninety- six per cent (131/137) of steroid- treated 
patients received oral corticosteroids. Median duration of 
oral corticosteroid treatment was 90 days (4–1365). Forty- 
four per cent (60/137) of steroid- treated patients were 
Box 1 List of diagnoses in patients with systemic 
diseases as causes of acute tubulointerstitial nephritis 
(TIN). Two patients were diagnosed with Sjögren’s 




















Fatigue 70% 119/171 0
Vomiting/nausea 49% 83/169 2
Fever 43% 73/171 0
Flank pain 33% 56/168 3
Arterial hypertension 22% 38/171 0
Oliguria/anuria 20% 35/171 0
Ocular symptoms 14% 24/169 2
Joint pain 14% 24/169 2
Exanthema 6% 11/171 0
Urinary features
Tubular proteinuria 72% 79/109 62
Glucosuria 56% 80/143 28
Glomerular proteinuria, non- nephrotic range (<1000 mg/m2 BSA/day in 24 hours 
urine collection or <2 g/g creatinine in spot urine sample)
53% 90/171 0
Microscopic haematuria 39% 66/170 1
Leukocyturia 29% 49/170 1
Glomerular proteinuria, nephrotic- range (>1000 mg/m2 BSA/day in 24 hours urine 
collection or >2 g/g creatinine in spot urine sample)
11% 19/171 0
Urinary eosinophilia 9% 7/78 93
Macroscopic haematuria 8% 14/169 2
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treated with intravenous corticosteroids with a median 
treatment duration (range) of 3 days (1–6).
Eighteen per cent (31/171) of all patients included 
in the study were treated with non- corticosteroid immu-
nosuppressive drugs. Of these, all but one patient 
(patient with TIN as a complication of autoimmune 
polyendocrinopathy- candidiasis- ectodermal dystrophy 
(APECED) type 1) were additionally treated with corti-
costeroids (oral and/or intravenous). MMF was the most 
frequently used non- corticosteroid immunosuppressant 
in 12% (21/171) of all cases. Details of immunosuppres-
sive treatment are given in table 4.
Renal function and residual damage
Serum creatinine levels were collected at time of renal 
biopsy, 2 weeks and 3–6 months later. Renal function 
parameters at biopsy were available for all 171 patients, 
serum creatinine levels 2 weeks and 3–6 months after renal 
biopsy were given for 168 and 164 patients, respectively.
For all patients, median eGFR rose significantly from 
31 (3–182) mL/min/1.73 m2 at renal biopsy to 86 
(7–169) mL/min/1.73 m2 3–6 months after renal biopsy 
(p<0.001). After 2 weeks, renal function had already 
significantly improved with a median eGFR of 67 mL/
min/1.73 m2 (5–167) (p<0.001) (see figure 3A). Signif-
icant improvement in renal function was detectable in 
every aetiological subgroup 2 weeks and 3–6 months after 
renal biopsy (see figure 3B and C). The median rise in 
eGFR was 22–96 mL/min/1.73 m2 in drug- induced TIN, 
36–85 mL/min/1.73 m2 in TINU syndrome, 36–81 mL/
min/1.73 m2 in idiopathic TIN, 35–72 mL/min/1.73 m2 
in TIN associated with systemic diseases and 28–98 mL/
min/1.73 m2 in TIN associated with infections.
eGFR was normalised (>90 mL/min/1.73 m2) in 41% 
(67/164; no data=7) after 3–6 months, 59% (97/164) had 
an impaired eGFR (<90 mL/min/1.73 m2). Most patients 
(47%=77/164) showed a mild reduction in glomerular 
filtration rate (60–89 mL/min/1.73 m2), while a mild 
to moderate impairment (30–59 mL/min/1.73 m2) was 
present in 9% (14/164). Only 3% (6/164) had eGFR 
<30 mL/min/1.73 m2 (see table 5).
Median eGFR after 3–6 months was 85 (8–168) mL/
min/1.73 m2 in the steroid group and 91 (7–135) mL/
min/1.73 m2 in the non- steroid group (p=0.10). Before 
initiation of treatment, steroid- treated patients had a 
significantly lower eGFR than patients who were not 
treated with steroids (30 mL/min/1.73 m2 compared with 
38 mL/min/1.73 m2) (p=0.03) (see table 6).
Seven per cent (12/171) needed renal replacement 
therapy either as haemodialysis (7/171) or peritoneal 
dialysis (5/171). Median duration (range) of renal 
replacement therapy was 6.5 (2–180) days. Seven (12/164; 
no data=7) of patients had glomerular proteinuria 3–6 
months after renal biopsy and in 19% (32/164) urinalysis 
showed persistent tubular proteinuria. Mixed proteinuria 
(glomerular and tubular) was detected in 9% (14/164). 
The majority of patients (65%=106/164) had no residual 
proteinuria. The prevalence of proteinuria (glomerular 
and/or tubular) did not differ between steroid- treated 
and untreated patients (p=0.50).
Arterial hypertension treated with medication was 
present in 19% (32/171), 17% (28/171) needed one 
or two antihypertensive drugs, 2% (4/171) were treated 
with three or more antihypertensives. Most patients 






and range (in mg/
kg/day)
Route of administration
  Oral CS, no intravenous 
CS
56%
  Intravenous CS, no oral 
CS
4%
  Oral+intravenous CS 40%
Substance
  Oral prednisone 31% 1.03 (0.40–2.33)
  Oral prednisolone 56% 1.00 (0.35–2.00)
  Oral methlyprednisolone 7% 0.97 (0.67–4.00)
  Intravenous prednisolone 7% 6.94 (0.66–22.73)
  Intravenous 
methylprednisolone
37% 10.81 (1.63–30.00)
  Unknown oral CS 1% –
CS, corticosteroids; IV, intravenous.
Table 4 Immunosuppressants in 31 patients with acute 
tubulointerstitial nephritis (TIN)
Immunosuppressant






Mycophenolate mofetil Drug- induced TIN (3), 
TINU (11), idiopathic TIN 
(5), systemic disease (2)
21
Azathioprine Drug- induced TIN (1), 
TINU (1), idiopathic TIN 
(3)
5
Cyclosporine TINU (1), idiopathic TIN 
(2)
3
Methotrexate TINU (2), systemic 
disease (1)
3
Cyclophosphamide Idiopathic TIN (1), 
systemic disease (1)
2
Rituximab Systemic disesase 1
Eculizumab Systemic disesase 1
Hydroxychloroquine Systemic disesase 1
More than one medication was administered in several cases.
TINU, tubulointerstitial nephritis with uveitis.
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(81%=139/171) did not need antihypertensive treat-
ment. Significantly more steroid- treated patients than 
patients without steroid treatment needed antihyperten-
sive treatment 3–6 months later (22% vs 6%, p=0.03).
DISCUSSION
The results of this survey shed some light on cause, clinical 
management and outcome of TIN in paediatric patients. 
To the best of our knowledge, our findings are from the 
largest paediatric TIN cohort to date.
The clinical presentation of TIN was unspecific with 
fatigue, vomiting or nausea and fever being the most 
frequent features. Only one patient of 171 (0.6%) showed 
the ‘classic’ triad of fever, arthralgia and skin rash or exan-
thema that dominated the clinical picture in early reports 
of mainly drug- induced cases. Actually, this symptom triad 
occurred in 5%–10% of patients in earlier reports.9 18
Drug- induced TIN is the underlying cause in 60%–70% 
of cases in adults.6 18 In our cohort, drugs were respon-
sible for only 30% of TIN cases. The fact that only biopsy- 
proven cases were included in our analysis might be 
responsible for a lower percentage of drug- induced cases 
since in clinical practice patients with typical clinical hall-
marks of drug- induced TIN and mild to moderate renal 
failure do not always undergo renal biopsy. NSAIDs and 
antimicrobials are the most common culprits in drug- 
induced TIN.6 19 Whether NSAIDs or antimicrobials are 
the leading class of drugs in the aetiology of TIN, however, 
is a matter of debate.1 11 20 21 In our paediatric cohort, 
NSAIDs were identified as the leading cause in 48% of 
patients with drug- induced TIN, and another 10% had a 
history of NSAIDs plus antimicrobial intake. Coadminis-
tration of two or more drugs can make it difficult to iden-
tify the culpable agent, but NSAIDs clearly represent the 
main cause for drug- induced TIN in our study, followed 
by antibiotics (21% of drug- induced cases). Although 
proton- pump inhibitors (PPIs) are a widely prescribed 
class of drugs and have been considered a relevant cause 
of acute TIN since the first published report of PPI- 
induced TIN in 1992,22–25 no case of PPI- induced TIN was 
found in our cohort.
Remarkably, three patients had a history of herbal 
medicine intake. Aristolochic acid and other plant alka-
loids have been identified as nephrotoxic ingredients in 
Chinese herbal medicine, and interstitial nephritis is one 
possible manifestation of its nephrotoxic capacity.26 27 
Furthermore, interstitial nephritis was triggered by bee 
stings in two patients. Acute kidney injury due to immune- 
mediated acute interstitial nephritis has been reported 
as a rare complication of Hymenoptera stings (bees and 
wasps) in a number of case reports or case series.28–30 
Another patient developed acute TIN after smoking a 
potentially nephrotoxic substance. A number of legal 
and illegal drugs should be taken into consideration as 
possible triggers of TIN, particularly in adolescents. For 
example, synthetic cannabinoids have become popular 
recreational drugs with Δ9- tetrahydrocannabinol- like 
effects that are solubilised, sprayed onto herbal mixtures 
and usually smoked. Renal manifestations of synthetic 
Figure 3 (A) Significant improvement of estimated glomerular filtration rate (eGFR) 2 weeks and 3–6 months after renal biopsy 
in patients with acute tubulointerstitial nephritis (TIN). (B and C) Significant improvement of GFR in all etiological subgroups with 
acute TIN. TINU, tubulointerstitial nephritis with uveitis.
Table 5 Development of estimated glomerular filtration 
rate (eGFR) (mL/min/1.73 m2)] 2 weeks and 3–6 months after 





≥90 60–89 30–59 15–29 <15
Biopsy 171 3% 11% 40% 27% 19%
2 weeks 168 20% 42% 34% 2% 2%
3–6 months 164 41% 47% 9% 1% 2%
Table 6 Development of estimated glomerular filtration rate 
(eGFR) in patients without corticosteroid treatment versus 




treatment (n=34) P value
Biopsy 30 (3–182) 38 (9–112) 0.03
2 weeks 67 (5–167) 67 (25–132) 0.86
3–6 months 85 (8–169) 91 (7–135) 0.10
Values for eGFR (mL/min/1.73 m2) are given as median with 
range.
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cannabinoid use are acute tubular necrosis and acute 
interstitial nephritis.31 Our results show that a variety of 
drugs, medications and toxic agents are involved in the 
pathogenesis of acute interstitial nephritis and should be 
considered as a potential aspect of the patient’s medical 
history.
TIN was associated with systemic diseases in 7% of 
patients. In adults, systemic diseases underlie 10%–15% 
of cases.19 Sjögren’s syndrome and sarcoidosis are well 
described autoimmune disorders with TIN as typical 
renal manifestation. Interstitial nephritis is the prevalent 
renal finding in Sjögren’s syndrome; 98% of patients with 
renal involvement show TIN in renal biopsy.32 TIN associ-
ated with APECED type 1,33 34 microscopic polyangiitis,35 
familial Mediterranean fever,36 37 rheumatoid arthritis38 
and malignant infiltration39 has been described in the 
literature. The case of a 17- year- old girl with atypical 
haemolytic uraemic syndrome and acute TIN included in 
our analysis has also been described by Basak et al.40
Infectious causes were found in 4% (in adults 
5%–10%19). Only viral and no bacterial, fungal or para-
sitic pathogens were identified. Adenovirus, BK polyoma 
virus (both predominantly in renal transplant patients) 
and hepatitis C have been described as infectious causes 
of TIN.41–43 Three patients had symptoms of upper 
respiratory tract infection without pathogen identifica-
tion, and rhinovirus was identified in another patient. It 
remains unclear if a bacterial or viral pathogen was the 
unequivocal cause of TIN in these cases or if other under-
lying factors played a role in the pathogenesis (eg, intake 
of NSAIDs or antibiotics to treat respiratory symptoms). 
It has to be noted that all diagnoses were established by 
the participating physicians based on biopsy results and 
clinical findings.
TINU is thought to be a rare condition with an inci-
dence of uveitis among TIN patients of less than 10%.18 
Jahnukainen et al44 reported that uveitis was diagnosed in 
46% in a case series of 26 children with ‘idiopathic TIN’, 
supporting the assumption that the prevalence of uveitis 
among TIN patients is higher than previously assumed. 
In our study, 58% of TINU patients had no ocular symp-
toms at onset of renal disease. This is in line with previous 
reports that uveitis may evolve up to 14 months after the 
onset of TIN45 46 and that a high percentage of TINU 
patients are ophthalmologically asymptomatic at the onset 
of renal symptoms.44 Thorough ophthalmological exam-
inations over months after the onset of TIN are necessary 
even in patients without ocular symptoms.44 46 Our results 
support the rationale for this recommendation.
In our study, the overall renal outcome 3–6 months 
after diagnosis of TIN was favourable with a rise in 
median eGFR from 31 to 86 mL/min/1.73 m2. Only 2% 
(two patients with idiopathic TIN, one patient with drug- 
induced TIN and another patient with systemic disease) 
had eGFR <15 mL/min/1.73 m2 (CKD 5).
The role of corticosteroids in the treatment of TIN 
has remained controversial. Available studies in adults 
are retrospective and not controlled and deliver partially 
contradictory results.1 11–15 A prospective paediatric study 
with 17 patients showed that prednisone speeds up renal 
recovery, but there was no significant difference in renal 
function between prednisone and control patients after 6 
months’ follow- up.16
In our study, renal function improved significantly after 
2 weeks and showed further significant improvement 
3–6 months after kidney biopsy. This development of 
eGFR was found in all aetiological subgroups. Cortico-
steroid treatment of TIN seems well established among 
paediatric nephrologists, since 80% of included patients 
received steroids. Whereas patients who were not treated 
with steroids had a significantly better median eGFR than 
patients who underwent steroid therapy at time of renal 
biopsy, there was no significant difference in eGFR 2 
weeks and 3–6 months later and the rate of glomerular 
and/or tubular proteinuria 3–6 months later. However, 
we were not able to evaluate the efficacy of corticosteroid 
treatment of acute TIN since the number of patients was 
not equally distributed between the steroid- treated and 
untreated group (80% receiving steroid treatment) and 
long- term effects of corticosteroid treatment were not 
monitored. MMF is an additional treatment option in 
paediatric TIN patients with different etiological back-
grounds but was exclusively used in combination with 
corticosteroids (the exception being one patient with 
APECED type 1 syndrome, treated with MMF and ritux-
imab). MMF has been described as a successful thera-
peutic option for steroid- resistant or intolerant patients.47
Strengths and limitations of our study
Our results are based on retrospective data collected in 
an online survey. This method of data collection requires 
concise and comprehensive questions but at the same 
time needs to be feasible and low threshold. We were not 
able to check the data for correctness but relied on the 
clinical data given by the participants.
Our follow- up period of 3–6 months is relatively short. 
In a larger and, at best, prospective study on paediatric 
TIN, we propose a follow- up period of at least 1 year. 
Biopsy results were not available as original copies apart 
from a few cases. Thus, we were not able to grade the 
degree of histological changes (eg, interstitial fibrosis). 
Ideally, all original biopsy samples should be re- evaluated 
by one pathologist. As many TIN patients with mild or 
moderate renal failure do not undergo kidney biopsy in 
all centres, severe cases were presumably over- represented 
in our study population.
The main strength of our study is the high number of 
patients and participating centres. It is the largest collec-
tion of children with TIN until now.
Conclusion
Data from this large cohort suggest an overall posi-
tive outcome of biopsy- proven acute TIN in paediatric 
patients. Eighty- eight per cent of patients showed no or 
mild impairment of renal function 3–6 months after TIN 
was diagnosed. Prospective randomised controlled trials 
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are required to determine the efficacy of corticosteroids 
in the management of acute TIN in paediatric patients.
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